United Kingdom

Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

5:06pm GMT
Change (% chg)

$0.01 (+0.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Chimerix Inc entered into agreement with Cowen and Co
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :On November 8, 2017, co entered into an at market issuance, or ATM, sales agreement with Cowen and Company LLC - SEC filing​.Under agreement co may offer and sell shares of its common stock, $0.001 per share, having aggregate gross proceeds of up to $75 million​.  Full Article

Chimerix reports Q3 loss of $0.37/shr
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Chimerix Inc :Chimerix announces third quarter 2017 financial results.Q3 loss per share $0.37.Q3 revenue $900,000 versus I/B/E/S view $850,000.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Q2 loss per share $0.39
Monday, 8 Aug 2016 

Chimerix Inc : Chimerix announces second quarter 2016 financial results . Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S .Q2 revenue $1.8 million versus I/B/E/S view $2 million.  Full Article

Chimerix Q1 loss per share $0.57
Monday, 9 May 2016 

Chimerix Inc : Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results . Q1 loss per share $0.57 . Q1 revenue $1.2 million . Q1 revenue view $2.8 million -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

Chimerix Inc presents positive results from brincidofovir pivotal study in animal model for smallpox
Monday, 8 Feb 2016 

Chimerix Inc:Presents positive results from brincidofovir pivotal study in animal model for smallpox.Study met its primary endpoint of clinically and statistically significant (p<0.05) reduction in mortality for brincidofovir-treated animals compared with animals that received placebo.Final data from the rabbitpox study together with efficacy data from a mouse model of smallpox will be submitted to the FDA for discussion of next steps.  Full Article

Chimerix Inc announces top-line results from Phase 3 SUPPRESS Trial of Brincidofovir
Monday, 28 Dec 2015 

Chimerix Inc:Announces top-line results from phase 3 suppress trial of brincidofovir.Says primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm.Says plans to continue the programs testing brincidofovir in serious adenovirus infections and in smallpox.Primary endpoint failures in prevention of cmv infections, mortality in brincidofovir ARM driven by confirmed cases of GVHD.Says non-statistically significant increase in mortality in the brincidofovir arm compared to the control arm.Chimerix has elected to pause further enrollment in the phase 3 sustain and surpass trials in kidney transplant recipients.Says SUPPRESS did not achieve primary endpoint for prevention of clinically significant CMV infection after HCT.  Full Article

UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant

Nov 9 Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.